Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel

NCT02586025 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

329

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: FEC Chemotherapy
PROCEDURE: Surgery
DRUG: Docetaxel
DRUG: Pertuzumab
DRUG: Placebo
DRUG: Trastuzumab

Sponsor

Hoffmann-La Roche